CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat diseases of aging, announced today that findings in the journal Nature demonstrate that Sirtris and Harvard have developed novel drug candidates that offer a promising, new approach to treating diseases of aging, including Type 2 Diabetes, by targeting SIRT1, a gene that controls the aging process.
